期刊文献+

拉米夫定联合阿德福韦治疗乙型肝炎后肝硬化的护理观察 被引量:4

Nursing Observation of Lamivudine Combined with Adefovir Dipivoxil in Treatment of Liver Cirrhosis Caused by Chronic Hepatitis
下载PDF
导出
摘要 目的:探讨乙型肝炎后肝硬化采用拉米夫定联合阿德福韦治疗的临床护理。方法:选择本院2009.2-2010.12门诊及住院乙型肝炎后肝硬化患者48例。采用拉米夫定联合阿德福韦治疗,并采取相应护理干预,对临床资料进行回顾性分析。结果:两组患者治疗前后血消ALT、AST比较均有明显恢复,但两组间比较差异无显著性,治疗2年后,治疗组的肝功能在正常范围内波动,而对照组时有肝功能异常。结论:在心理支持、服药过程中的监护、出院指导等方面进行更加规范的指导,可以提高治疗效果和患者的生活质量,延长生存时间,提高成活率。 Objective:To study the clinical nursing of lamivudine combined with adefovir dipivoxil in treatment of liver cirrhosis caused by chronic hepatitis.Methods:Total 48 outpatients and inpatients in our hospital from Feb.2009 to Dec.2010 with liver cirrhosis due to chronic hepatitis were included in this study.To remedy the patients by lamivudine combined with adefovir dipivoxil as well as nursing intervention related,then do retrospective analysis about clinical data.Results:Serum ALT and AST from both two groups recovered obviously after the treatment,but no significantly discrepancy between the groups.After two years' continuous treatment,liver function of patients from trial group using combination of lamivudine and adefovir dipivoxil works well within the normal scope,however, patients from control group have abnormal on liver function.Conclusion:The standard guidance of psychological support,nursing for taking drug and direction about discharging from hospital can improve the treatment effect and life quality of patients,meanwhile,extend their lifetime and enhance the survival rate.
作者 张余芬
出处 《中国医药导刊》 2011年第12期2177-2178,共2页 Chinese Journal of Medicinal Guide
关键词 拉米夫定 阿德福韦 乙型肝炎后肝硬化 护理 Lamivudine Adefovir dipivoxil Liver cirrhosis caused by chronic hepatitis Nursing
  • 相关文献

参考文献6

二级参考文献47

  • 1Colonno RJ, Genovesi EV, Medina L, et al. Long-term entecavir treatment results in sustained antiviral efficacy and prolonged life span in the woodchuck model of chronic hepatitis infection [ J] . J Infect Dis, 2001,184 (10): 1236.
  • 2Gish RG, LeungNWY, WrightTL, etal. Doserange study of pharmacokinetics, safety, and preliminary antiviral activity of emtricitabine in adults with hepatitis B virus infection [ J] . Antimicrob Agents Chemother,2002, 46(6): 1734.
  • 3Das K, Xiong X, Yang H, et al. Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC) [ J] . J Virol, 2001,75(10):4771.
  • 4Van Bommel F, Schemick A, Hopf U, et al. Tenofovir disoproxil fumarate exhibits strong antiviral effect in a patient with lamivudine-resistant severe hepatitis B reactivation [J] . Gastroenterology, 2003, 124(2):586.
  • 5Ristig MB, Crippin J, Aberg JA, et al. Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-coinfected individuals for whom interferon-alpha and lamivudine therapy have failed [J] . J Infect Dis,
  • 6Peek SF, Cote PJ, Jacob JR, et al. Antiviral activity of clevudine [L-FMAU, (1-(2-fluoro-5-methyl-beta, L-arabinofuranosyl) uracil)] against woodchuck hepatitis virus replication and gene expression in chronically infected woodchucks (Marmota monax) [ J]
  • 7Ying C, De Clercq E, Nicholson W, et al. Inhibition of the replication of the DNA polymerase M550V mutation variant of human hepatitis B virus by adefovir, tenofovir, L-FMAU, DAPD, penciclovir and lobucavir[J]. J Viral Hepat, 2000, 7(2): 161.
  • 8Dienstag JL, Perrillo RP, Schiff ER, et al. A preliminary trial of lamivudine for chronic hepatitis B infection[J]. N Engl J Med, 1995, 333(25): 1657.
  • 9Barcena MR, Cid GL, Lopez SP. Use ofadefovir in the treatment of the chronic hepatitis B virus infection with resistance to lamivudine [ J] . Transplant Proc, 2003,35(5):1841.
  • 10Perrillo R, Schiff E, Yoshida E, et al. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants [J] . Hepatology, 2000, 32(1): 129.

共引文献14210

同被引文献23

引证文献4

二级引证文献35

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部